Symbols / KALV $20.19 +1.46% KalVista Pharmaceuticals, Inc.

Healthcare • Biotechnology • United States • NGM
KALV Chart
About

KalVista Pharmaceuticals, Inc., a biopharmaceutical company, develops oral therapies for individuals for rare diseases with unmet needs. Its lead product candidate is EKTERLY, a fast-acting potent inhibitor of plasma kallikrein for the treatment of acute attacks of hereditary angioedema (HAE). The company is also developing is developing an orally disintegrating tablet formulation; KONFIDENT-KID for pediatric use with HAE; KONFIDENT; and KONFIDENT-S to evaluate sebetralstat and ODT formulation in adolescent and adult patients. KalVista Pharmaceuticals, Inc. is headquartered in Framingham, Massachusetts.

Fundamentals
Scroll to Statements
Sector Healthcare Industry Biotechnology Market Cap 1.03B
Enterprise Value 1.00B Income -164.29M Sales 73.62M
Book/sh -0.05 Cash/sh 5.86 Dividend Yield —
Payout 0.00% Employees 275 IPO —
P/E — Forward P/E 19.15 PEG —
P/S 14.05 P/B -380.94 P/C —
EV/EBITDA -6.09 EV/Sales 13.63 Quick Ratio 5.43
Current Ratio 5.58 Debt/Eq — LT Debt/Eq —
EPS (ttm) -3.94 EPS next Y 1.05 EPS Growth —
Revenue Growth — Earnings 2026-05-05 ROA —
ROE — ROIC — Gross Margin 25.73%
Oper. Margin -21.22% Profit Margin -223.16% Shs Outstand 51.22M
Shs Float 27.92M Short Float 42.91% Short Ratio 23.09
Short Interest — 52W High 21.30 52W Low 9.23
Beta -0.40 Avg Volume 1.07M Volume 1.30M
Target Price $34.33 Recom Strong_buy Prev Close $19.90
Price $20.19 Change 1.46%
Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$34.33
Mean price target
2. Current target
$20.19
Latest analyst target
3. DCF / Fair value
$34.33
Proxy: analyst mean price target (no FCF/EPS data available).
Ratings
Current target
$20.19
Low
$22.00
High
$42.00
Mean
$34.33

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-03-26 main Stifel Buy → Buy $42
2026-03-26 main Citizens Market Outperform → Market Outperform $28
2026-03-25 main Needham Buy → Buy $36
2026-01-09 main HC Wainwright & Co. Buy → Buy $37
2026-01-09 main Needham Buy → Buy $35
2026-01-06 main Needham Buy → Buy $32
2025-12-04 reit Needham Buy → Buy $28
2025-11-11 main Citizens Market Outperform → Market Outperform $28
2025-09-12 reit Needham Buy → Buy $28
2025-09-12 main JMP Securities Market Outperform → Market Outperform $28
2025-07-11 reit HC Wainwright & Co. Buy → Buy $27
2025-07-08 main JMP Securities Market Outperform → Market Outperform $27
2025-07-08 main HC Wainwright & Co. Buy → Buy $27
2025-07-07 main Leerink Partners Outperform → Outperform $20
2025-04-08 reit Needham Buy → Buy $28
2025-03-26 reit Needham Buy → Buy $28
2025-03-26 reit Citizens Capital Markets Market Outperform → Market Outperform $19
2025-03-26 main Jones Trading Buy → Buy $30
2025-03-14 reit HC Wainwright & Co. Buy → Buy $20
2025-03-13 reit Needham Buy → Buy $28
News
RSS: Latest KALV news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-03-26 VENROCK HEALTHCARE CAPITAL PARTNERS III, L.P. Beneficial Owner of more than 10% of a Class of Security — 214,631 $16.95 $3,691,148
2026-03-09 PALLEIKO BENJAMIN L Chief Executive Officer — 6,693 $16.08 $107,633
2026-03-06 PALLEIKO BENJAMIN L Chief Executive Officer — 15,625 — —
2026-02-23 AUDHYA PAUL K Officer — 5,354 $15.57 $83,345
2026-02-23 PALLEIKO BENJAMIN L Chief Executive Officer — 10,034 $15.57 $156,197
2026-02-23 YEA CHRISTOPHER M Officer — 4,347 $15.57 $67,669
2026-02-23 PIEKOS BRIAN Chief Financial Officer — 1,767 $15.57 $27,507
2026-02-23 SWEENY NICOLE Officer — 3,975 $15.57 $61,878
2026-02-20 PALLEIKO BENJAMIN L Chief Executive Officer — 23,250 — —
2026-02-20 YEA CHRISTOPHER M Officer — 6,875 — —
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-04-30 2024-04-30 2023-04-30 2022-04-30
Total Revenue
0.00
0.00
0.00
0.00
Operating Revenue
0.00
0.00
0.00
0.00
Operating Expense
182.98
+38.63%
131.99
+38.81%
95.09
+16.94%
81.31
Research And Development
71.71
-16.78%
86.17
+7.34%
80.28
+14.41%
70.17
Selling General And Administration
116.29
+114.24%
54.28
+77.41%
30.59
+15.69%
26.45
General And Administrative Expense
116.29
+114.24%
54.28
+77.41%
30.59
+15.69%
26.45
Other Gand A
116.29
+114.24%
54.28
+77.41%
30.59
+15.69%
26.45
Total Expenses
182.98
+38.63%
131.99
+38.81%
95.09
+16.94%
81.31
Operating Income
-182.98
-38.63%
-131.99
-38.81%
-95.09
-16.94%
-81.31
Total Operating Income As Reported
-188.00
-33.86%
-140.44
-26.67%
-110.87
-14.76%
-96.61
EBITDA
-173.33
-37.75%
-125.83
-33.34%
-94.37
-16.87%
-80.75
Normalized EBITDA
-175.61
-37.96%
-127.29
-34.96%
-94.32
-19.96%
-78.63
Reconciled Depreciation
0.94
+15.32%
0.82
+13.65%
0.72
+27.30%
0.56
EBIT
-174.27
-37.60%
-126.64
-33.19%
-95.09
-16.94%
-81.31
Total Unusual Items
2.28
+55.98%
1.46
+3085.71%
-0.05
+97.69%
-2.12
Total Unusual Items Excluding Goodwill
2.28
+55.98%
1.46
+3085.71%
-0.05
+97.69%
-2.12
Net Income
-183.44
-44.85%
-126.64
-36.31%
-92.91
-12.83%
-82.34
Pretax Income
-180.05
-42.17%
-126.64
-36.31%
-92.91
-12.83%
-82.34
Net Non Operating Interest Income Expense
0.65
-83.32%
3.90
+74.55%
2.23
+104.77%
1.09
Interest Expense Non Operating
5.79
0.00
—
—
Net Interest Income
0.65
-83.32%
3.90
+74.55%
2.23
+104.77%
1.09
Interest Expense
5.79
0.00
—
—
Interest Income Non Operating
6.43
+65.17%
3.90
+74.55%
2.23
+104.77%
1.09
Interest Income
6.43
+65.17%
3.90
+74.55%
2.23
+104.77%
1.09
Other Income Expense
2.28
+56.85%
1.45
+2841.51%
-0.05
+97.50%
-2.12
Other Non Operating Income Expenses
-0.00
+70.00%
-0.01
-150.00%
-0.00
-300.00%
-0.00
Gain On Sale Of Security
2.28
+55.98%
1.46
+3085.71%
-0.05
+97.69%
-2.12
Tax Provision
3.39
0.00
0.00
0.00
Tax Rate For Calcs
0.00
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.48
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-183.44
-44.85%
-126.64
-36.31%
-92.91
-12.83%
-82.34
Net Income From Continuing Operation Net Minority Interest
-183.44
-44.85%
-126.64
-36.31%
-92.91
-12.83%
-82.34
Net Income From Continuing And Discontinued Operation
-183.44
-44.85%
-126.64
-36.31%
-92.91
-12.83%
-82.34
Net Income Continuous Operations
-183.44
-44.85%
-126.64
-36.31%
-92.91
-12.83%
-82.34
Normalized Income
-185.25
-44.60%
-128.11
-37.96%
-92.86
-15.75%
-80.22
Net Income Common Stockholders
-183.44
-44.85%
-126.64
-36.31%
-92.91
-12.83%
-82.34
Diluted EPS
-3.69
-7.27%
-3.44
-3.30%
-3.33
+0.89%
-3.36
Basic EPS
-3.69
-7.27%
-3.44
-3.30%
-3.33
+0.89%
-3.36
Basic Average Shares
49.65
+34.98%
36.79
+31.89%
27.89
+13.97%
24.47
Diluted Average Shares
49.65
+34.98%
36.79
+31.89%
27.89
+13.97%
24.47
Diluted NI Availto Com Stockholders
-183.44
-44.85%
-126.64
-36.31%
-92.91
-12.83%
-82.34
Other Taxes
-5.01
+40.68%
-8.45
+46.46%
-15.79
-3.15%
-15.30
Line Item Trend 2024-04-30
Total Assets
235.40
Current Assets
225.69
Cash Cash Equivalents And Short Term Investments
210.40
Cash And Cash Equivalents
31.79
Other Short Term Investments
178.61
Receivables
10.87
Accounts Receivable
0.00
Other Receivables
—
Taxes Receivable
9.46
Accrued Interest Receivable
1.41
Inventory
0.00
Raw Materials
0.00
Work In Process
0.00
Finished Goods
0.00
Prepaid Assets
4.42
Other Current Assets
—
Total Non Current Assets
9.71
Net PPE
9.15
Gross PPE
12.86
Accumulated Depreciation
-3.71
Properties
0.00
Machinery Furniture Equipment
0.67
Other Properties
9.33
Leases
2.86
Other Non Current Assets
0.57
Total Liabilities Net Minority Interest
28.82
Current Liabilities
22.81
Payables And Accrued Expenses
14.82
Payables
9.11
Accounts Payable
9.11
Current Accrued Expenses
5.71
Pensionand Other Post Retirement Benefit Plans Current
6.69
Current Debt And Capital Lease Obligation
1.30
Current Capital Lease Obligation
1.30
Current Deferred Liabilities
0.00
Current Deferred Revenue
0.00
Other Current Liabilities
—
Total Non Current Liabilities Net Minority Interest
6.01
Long Term Debt And Capital Lease Obligation
6.01
Long Term Debt
—
Long Term Capital Lease Obligation
6.01
Non Current Deferred Liabilities
0.00
Non Current Deferred Revenue
0.00
Stockholders Equity
206.58
Common Stock Equity
206.58
Capital Stock
0.04
Common Stock
0.04
Share Issued
42.52
Ordinary Shares Number
42.52
Treasury Shares Number
0.00
Additional Paid In Capital
679.75
Retained Earnings
-469.73
Gains Losses Not Affecting Retained Earnings
-3.49
Other Equity Adjustments
-3.49
Total Equity Gross Minority Interest
206.58
Total Capitalization
206.58
Working Capital
202.88
Invested Capital
206.58
Total Debt
7.32
Capital Lease Obligations
7.32
Net Tangible Assets
206.58
Tangible Book Value
206.58
Current Provisions
—
Interest Payable
0.00
Line Item Trend 2025-04-30 2024-04-30 2023-04-30 2022-04-30
Operating Cash Flow
-152.91
-71.36%
-89.23
-18.56%
-75.26
+3.68%
-78.13
Cash Flow From Continuing Operating Activities
-152.91
-71.36%
-89.23
-18.56%
-75.26
+3.68%
-78.13
Net Income From Continuing Operations
-183.44
-44.85%
-126.64
-36.31%
-92.91
-12.83%
-82.34
Depreciation Amortization Depletion
0.94
+15.32%
0.82
+13.65%
0.72
+27.30%
0.56
Depreciation And Amortization
0.94
+15.32%
0.82
+13.65%
0.72
+27.30%
0.56
Other Non Cash Items
6.24
+52116.67%
-0.01
-114.29%
0.08
-53.07%
0.18
Stock Based Compensation
12.29
-43.92%
21.91
+120.87%
9.92
-10.50%
11.09
Operating Gains Losses
-3.99
-605.49%
-0.56
+61.80%
-1.48
-169.34%
2.13
Gain Loss On Investment Securities
0.19
+114.26%
-1.32
-1053.24%
0.14
-76.08%
0.58
Net Foreign Currency Exchange Gain Loss
-4.17
-649.34%
0.76
+146.97%
-1.62
-204.25%
1.55
Change In Working Capital
15.04
-0.87%
15.17
+104.60%
7.41
+160.16%
-12.32
Change In Receivables
-3.62
-144.31%
8.18
+453.02%
-2.32
+55.47%
-5.20
Change In Prepaid Assets
-1.36
-152.42%
-0.54
-108.04%
6.69
+172.09%
-9.28
Change In Payables And Accrued Expense
9.46
+25.62%
7.53
+147.75%
3.04
+40.76%
2.16
Change In Accrued Expense
14.43
+349.64%
3.21
+66.10%
1.93
+309.32%
0.47
Change In Payable
-4.97
-215.07%
4.32
+290.24%
1.11
-34.38%
1.69
Change In Account Payable
-4.97
-215.07%
4.32
+290.24%
1.11
-34.38%
1.69
Change In Other Working Capital
10.56
—
—
—
Change In Other Current Assets
—
—
—
—
Investing Cash Flow
91.02
+207.44%
-84.72
-304.56%
41.41
-28.42%
57.86
Cash Flow From Continuing Investing Activities
91.02
+207.44%
-84.72
-304.56%
41.41
-28.42%
57.86
Net PPE Purchase And Sale
-0.43
-933.33%
-0.04
+96.49%
-1.20
-28.46%
-0.93
Purchase Of PPE
-0.43
-933.33%
-0.04
+96.49%
-1.20
-28.46%
-0.93
Capital Expenditure
-0.93
-109.71%
-0.44
+62.96%
-1.20
-28.46%
-0.93
Capital Expenditure Reported
-0.49
-23.44%
-0.40
0.00
0.00
Net Investment Purchase And Sale
91.95
+209.11%
-84.28
-297.78%
42.61
-27.52%
58.79
Purchase Of Investment
-30.57
+83.84%
-189.23
-92.61%
-98.25
+28.25%
-136.92
Sale Of Investment
122.52
+16.74%
104.95
-25.49%
140.86
-28.03%
195.71
Financing Cash Flow
159.73
+5.98%
150.71
+159.33%
58.12
+3575.90%
1.58
Cash Flow From Continuing Financing Activities
159.73
+5.98%
150.71
+159.33%
58.12
+3575.90%
1.58
Net Issuance Payments Of Debt
—
—
—
0.00
Repayment Of Debt
—
—
—
0.00
Long Term Debt Payments
—
—
—
0.00
Net Long Term Debt Issuance
—
—
—
0.00
Net Common Stock Issuance
55.91
-42.33%
96.94
+71.34%
56.58
0.00
Proceeds From Stock Option Exercised
5.78
-89.26%
53.77
+3405.15%
1.53
-2.97%
1.58
Net Other Financing Charges
98.04
—
—
—
Changes In Cash
97.84
+521.09%
-23.24
-195.74%
24.27
+229.83%
-18.69
Effect Of Exchange Rate Changes
2.64
+317.56%
-1.21
-198.14%
1.24
+205.91%
-1.17
Beginning Cash Position
31.79
-43.47%
56.24
+82.99%
30.73
-39.26%
50.59
End Cash Position
132.27
+316.09%
31.79
-43.47%
56.24
+82.99%
30.73
Free Cash Flow
-153.84
-71.55%
-89.67
-17.29%
-76.46
+3.30%
-79.06
Amortization Of Securities
0.01
-84.78%
0.09
-90.69%
0.99
-61.48%
2.56
Common Stock Issuance
55.91
-42.33%
96.94
+71.34%
56.58
0.00
Issuance Of Capital Stock
55.91
-42.33%
96.94
+71.34%
56.58
0.00
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category